Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Reservoir dispute for large municipality
Represented large municipality with regard to the challenge of a potential new reservoir, which would have the effect of removing the city’s existing more
Represented group of franchisees who acquired franchise system from their franchisor in settlement of litigation
Represented group of franchisees who acquired franchise system from their franchisor in settlement of litigation and converted the system into a more
Special Committee considering strategic alternatives
Represented Independent board members of a North Carolina-based NYSE-listed services business in connection with their consideration of strategic more
EPCRA and RCRA compliance for a leading tobacco company's facilities
Advising a leading tobacco company on EPCRA and RCRA compliance for company's facilities that included tobacco manufacturing and processing, more